- Sections
- C - Chimiemétallurgie
- C07D - Composés hétérocycliques
- C07D 207/24 - Atomes d'oxygène ou de soufre
Détention brevets de la classe C07D 207/24
Brevets de cette classe: 95
Historique des publications depuis 10 ans
|
3
|
7
|
13
|
5
|
3
|
8
|
7
|
7
|
5
|
3
|
| 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | 2026 |
Propriétaires principaux
| Proprétaire |
Total
|
Cette classe
|
|---|---|---|
| Omeros Corporation | 307 |
5 |
| Novartis AG | 10170 |
4 |
| Vettore, LLC | 17 |
4 |
| Pfizer Inc. | 3423 |
3 |
| Merck Patent GmbH | 5751 |
3 |
| BioCryst Pharmaceuticals, Inc. | 185 |
3 |
| The United States of America, as represented by the Secretary, Department of Health and Human Services | 3024 |
3 |
| Bristol-myers Squibb Company | 4747 |
2 |
| 3m Innovative Properties Company | 17443 |
2 |
| Janssen Pharmaceutica N.V. | 3137 |
2 |
| Northwestern University | 3586 |
2 |
| Eli Lilly and Company | 4134 |
2 |
| MedImmune Limited | 611 |
2 |
| National Institute of Biological Sciences, Beijing | 102 |
2 |
| NDSU Research Foundation | 250 |
2 |
| Shanghai Puyi Chemical Technology Co. Ltd | 2 |
2 |
| Vironova Thionation AB | 5 |
2 |
| Suzhou Abogen Biosciences Co., Ltd. | 81 |
2 |
| ReNAgade Therapeutics Management Inc. | 64 |
2 |
| Miralogx LLC | 51 |
2 |
| Autres propriétaires | 44 |